2025

September 29, 2025

Invited speaker at 9th Annual MASH Drug Development Summit (Boston, MA)

September 1, 2025

NIH NIA Phase 2 grant awarded to advance NNMT inhibitor drugs that preserve muscle during GLP-1 mediated weight loss.

April 16, 2025 

NIH NIA review panel recommends funding of Ridgeline Phase 2 SBIR grant

March 14, 2025 

DoD Notice of Award to fund development of NNMT inhibitors to prevent osteoarthritis and speed recovery following traumatic joint injury

Feb 21, 2025

Ridgeline CEO served on VA grant review panel

2024

Dec 16, 2024

Ridgeline team's article on hip fracture's unique mortality risk highlighted as Most Viewed JMIR Aging article in 2024

Oct 2, 2024

Ridgeline Interview: Strength while Aging

Aug 15, 2024

New small-molecule drug may help people stay strong as they age

July 16, 2024

Ridgeline staff served on an NIH Small Business grant review panel

July 5, 2024

Paper on NNMT Inhibitor Treatment Mimicking & Boosting Exercise-mediated Benefits to Aged Muscles

June 25, 2024

NIH NIA Award for GLP Minipig Safety/Toxicity Studies of a New Drug to Enhance Muscle Function

June 20-21, 2024

Ridgeline staff served on an NIH Small Business grant review panel

June 11, 2024

Ridgeline Speaks on Citeline Regulatory Podcast: Navigating IND Applications & Pre-IND Meetings

May 13-15, 2024

Ridgeline Invited to Abu Dhabi Global Healthcare Week as Healthcare Leader

Feb 26-27, 2024

Ridgeline Invited as Key Opinion Leader for BIO CEO & Investor Conference (New York, NY)

Feb 13-14, 2024

Ridgeline staff served on an NIH grant review panel

2023

Nov 16, 2023

Ridgeline staff served on an NIH Small Business grant review panel

Nov 26-29, 2023

Ridgeline Invited to be Key Speaker at 7th Obesity & Nash Drug Summit (Boston, MA)

Aug 23, 2023

NIH NIA Award for a Small Molecule Oral Drug to Prevent and Reverse Skeletal Muscle Atrophy in Aging Adults

June 27-28, 2023

Ridgeline staff served on an NIH Small Business grant review panel

May 26, 2023

NIH NIA Award for Preclinical Development of a New Drug to Boost Muscle Function Post Hip Fracture

Feb 21, 2023

News Report: Preclinical Advancement of New Mechanism-of-Action Drug to Combat Type 2 Diabetes in US Veterans

2022

Nov 30 - Dec 1, 2022

Ridgeline Presented at the 6th Obesity & NASH Drug Development Summit

Dec 7-8, 2022

Ridgeline Represented in a Panel on Optimizing Trial Success with Your CRO (Outsourcing in Clinical Trials Texas)

Oct 20, 2022

‘If you can preserve muscle strength, you will age healthier’

Sep 28-29, 2022

Ridgeline Therapeutics Presented at the Longevity Investors Conference

Sep 26-29, 2022

Ridgeline Therapeutics Presented at the Defense Tech Connect Conference

June 13-16, 2022

Ridgeline was an NIH-Sponsored showcase at the Innovation Zone/on the Innovation Stage (BIO International)

April 28-30, 2022

Ridgeline Therapeutics Presented at the 3rd International Conference on Fatty Liver

Mar 23-25, 2022

Ridgeline in the Geroscience Task Force (Challenge in Developing Geroscience Drug Trials) at Euro-Geroscience

Mar 18, 2022

Ridgeline staff served on an NIH Small Business grant review panel

Mar 16, 2022

News Report: NIH and DoD-backed Ridgeline Targets Muscle Decline

Mar 15, 2022

Ridgeline staff served on an NIH grant review panel

Mar 9, 2022

Paper Published on the 1-Year Post-Fracture Mortality Rate in Older Adults with Hip Fractures vs. Other Fractures

Feb 24, 2022

Ridgeline Therapeutics Presented at the Annual Texas Life Science Forum

Jan 10, 2022

Paper Published on The Obese Mouse Microbiome After NNMT Inhibition Combined with Reduced-Calorie Diet

2021

Nov 18, 2021

Ridgeline staff served on an NIH Small Business grant review panel

Sep 22, 2021

Ridgeline Therapeutics awarded a Catalyst Award by the National Academy of Medicine

Sep 20, 2021

NIH NIA Award for Preclinical Development of a New Drug to Enhance Muscle Function Post Hip Fracture

Sep 20, 2021

Peer-Reviewed Paper on Development and Validation of an LC-MS/MS Assay for Our Probe NNMT Inhibitor

Mar 11, 2021

Paper on NNMT Inhibitor Combined with Reduced-Calorie Diet Normalizing Body Composition in Obese Mice

Jan 27-28, 2021

Ridgeline staff served on a DoD grant review panel

2020

Oct 29, 2020

News Report: Texas is “Going Big” in Biopharma

Jun 8-12, 2020

Ridgeline Sponsored by the NIH Office of Small Business Research to Present at BIO Digital/ be in the Innovation Zone

May, 2020

Ridgeline Therapeutics Selected for the NIH NIA Office of Small Business Research Biotech Showcase

Apr 21-22, 2020

Ridgeline Selected as 1 of 10 Emerging Companies for the Biotech Showcase (Longevity Leaders World Congress)

2019

Nov 6, 2019

News Report: Can Our Muscles Stay Young Even As We Get Old?

Oct 29, 2019

Ridgeline Therapeutics Presented at the ADME: Lead Characterization and Optimization Conference

Oct 16-17, 2019

Ridgeline Gave a Keynote Presentation at the 4th Annual European Drug Discovery Strategic Summit

Sep 16, 2019

NIH NIAMS Award to Validate the Preclinical Efficacy of Novel Inhibitors to Treat Duchenne Muscular Dystrophy

Sep 11-12, 2019

Ridgeline Therapeutics Presented at the Outsourcing in Clinical Trials Texas Conference

Jul 15, 2019

DoD Award for Safety & Efficacy Studies to Advance New Drugs to Treat Obesity-linked Type 2 Diabetes

Apr 13, 2019

News Report: UTMB Scientists Develop Drug to Rejuvenate Muscle Growth

Mar 6, 2019

News Report: This Houston Biotech Company Hopes to One Day Fix Your Aging Muscles

Feb 10, 2019

Peer-Reviewed Paper on an NNMT Inhibitor To Improve the Regenerative Capacity of Aged Skeletal Muscle

Jan 6-9, 2019

Ridgeline Presented at the exclusive Biotech Showcase for investors at J.P. Morgan Healthcare

2018

Nov, 2018

Ridgeline Presented in the U.S.-China Innovation & Investment Summit Grand Finals

Oct 5, 2018 

Ridgeline Therapeutics Spoke at the Regenerative Medicine in Aging Symposium at Rice University

Sep 18, 2018

NIH NIA Award for Safety & Efficacy Studies to Advance Drugs to Reverse Age-related Muscle Degeneration

Aug 21, 2018

NIH NIDDK Award for Safety & Efficacy Studies to Advance Novel Obesity-linked Type 2 Diabetes Treatments

Jul 27, 2018

Podcast: The Impossible Problem - Weight Loss

Jul 24, 2018

Ridgeline Therapeutics anti-obesity and anti-Type 2 diabetes drug technology selected for Top 100 Science Spinoffs

May 14-15, 2018

Ridgeline Therapeutics Awarded First Place at the US-China Investment and Innovation Summit

Apr 24, 2018

Ridgeline Therapeutics Selected as a Finalist in the 2018 Diabetes Innovation Challenge

Feb 20, 2018

News Report: Pill to Shrink Your Fat in the Works

Jan 24, 2018

News Report: New Drug May Be Ultimate Pharmaceutical Grail For People With Obesity

Jan 15, 2018

News Report: When You Hit A Weight Loss Plateau, New Medical Research Could Help You Break Through

Jan 10, 2018

News Report: Anti-Obesity and Diabetes Drug Shows Promise in Early Experiments

Jan 8, 2018

News Report: New Drug Could 'Shrink' Harmful Fat Cells

Jan 5, 2018

News Report: This Obesity Fighting Drug Could Melt Fat and Lower Cholesterol

Jan 5, 2018

News Report: UTMB Develops Anti-Obesity Drug to Shrink Fat Without Eating Less

2017

Nov 15, 2017

Peer-Reviewed Scientific Publication on Nicotinamide N-Methyltransferase Inhibitors to Treat Diet-Induced Obesity

May 26, 2017

Peer-Reviewed Scientific Publication on Small Molecule Nicotinamide N-Methyltransferase Inhibitors

tes

test